NCT07725822尚未招募4 期
An Open Label Trial to Evaluate Efficacy and Safety of Roflumilast 0.3% Cream for Chronic Plaque and Nail Psoriasis
Modern Research Associates, PLLC1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2026年8月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Mean Change in NAPSI
研究概览
简要总结
This is an open label trial in subjects ≥12 years of age and older with chronic plaque psoriasis and moderate to severe nail psoriasis.
Eligible participants will apply roflumilast 0.3% cream daily for 24 weeks to affected nails daily for the entire study duration and to psoriasis plaques daily until clear.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants legally competent to sign and give informed consent.
- •Males and females ages 12 years of age and older.
- •Clinical diagnosis of psoriasis vulgaris of at least 6 months duration as determined by the Investigator. Stable psoriasis for the past 6 months and stable nail disease for the past 6 months.
- •Psoriasis vulgaris on the face, extremities, trunk, and/or intertriginous areas and groin (excluding the scalp, palms and soles).
- •Nail psoriasis affecting ≥3 fingernails on hands.
- •An Investigator's Global Assessment of disease severity (IGA) or (I-IGA) of at least Almost Clear ('1') at Baseline
- •Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) (if not combined).
- •In addition, sexually active FOCBP must agree to use at least one form of highly effective contraception throughout the trial.
- •Highly effective forms of contraception include: oral/implant/injectable/transdermal contraceptives, intrauterine device, and partner's vasectomy.
- •If barrier methods are used (e.g., condom with spermicide, diaphragm with spermicide), then 2 forms of conception are required.
- •The use of abstinence as a contraceptive measure is acceptable as long as this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.
- •In good health as judged by the Investigator, based on medical history, physical examination.
排除标准
- •Subjects who cannot discontinue medication and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (Table 1).
- •Subjects who currently have or plan to have gel or acrylic overlays on nails during the study.
- •Subjects who cannot discontinue nail care habits that will confound efficacy and safety assessments (e.g. buffing, filing, excessive trimming). Routine simple clipping is allowed.
- •Subjects who cannot discontinue any nail topcoat products (e.g. hardeners, strengtheners, nail polish) Simple nail polish will be allowed for special events and removed the next day. Subject will note in diary days this occurs and the total days may not exceed 5 study days.
- •Planned excessive exposure of treated area(s) to either natural or artificial sunlight, tanning bed or other LED.
- •Subjects currently taking lithium or antimalarial drugs.
- •Planned initiation or changes to concomitant medication that could, in the opinion of the Investigator, affect psoriasis vulgaris (e.g. beta blockers, ACE inhibitors).
- •Current diagnosis of drug-induced psoriasis.
- •Any recent infection, presence of onychomycosis or any other confounding nail disorder as determined by investigator.
- •Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.
- •Known allergies to excipients in roflumilast cream (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphate and ceteth-10 phosphate).
- •Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.
- •Previous treatment with any topical PDE4i. Subjects who have received oral roflumilast (Daliresp®, Daxas®) or other PDE4 inhibitors (apremilast) within the past 6 months.
- •Known or suspected:
- •severe renal insufficiency or moderate to severe liver impairment (Child-Pugh B or C)
- •known HIV infection
- •hypersensitivity to component(s) of the study drugs
- •history of severe depression, suicidal ideation
- •Subjects with a history of chronic alcohol or drug abuse within 6 months of initiation of study medication.
- •Subjects with a history of a major surgery within 4 weeks prior to Baseline (Visit 2) or has a major surgery planned during the study.
- •Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.
- •Subjects who are family members of the clinical study site, clinical study staff / sponsor, or family members of enrolled subjects.
- •Subjects with any serious medical condition or laboratory abnormality that would prevent study participation or place the subject at significant risk, as determined by the Investigator.
- •History of and/or concurrent condition of serious hypersensitivity (anaphylactic shock or anaphylactoid reaction) to PDE-4 inhibitors.
- •Current or a history of cancer within 5 years with the exception of fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.
研究组 & 干预措施
Roflumilast 0.3% topical cream
Experimental
干预措施: Roflumilast 0.3% topical cream (Drug)
结局指标
主要结局
Mean Change in NAPSI
时间窗: 24 weeks
The Primary Efficacy Endpoint is NAPSI mean change from baseline at week 24
Mean Change in Nail Psoriasis Severity Index (NAPSI)
时间窗: 24 weeks
The Primary Efficacy Endpoint is NAPSI mean change from baseline at week 24
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
A study to compare how well different Sorozema treatments work and how safe they are in adults with a common scaly skin condition.CTRI/2025/12/098454Nisarga Biotech Pvt. Ltd.35
尚未招募
2/3 期
Evaluating the safety and efficacy of Unani formulations in PsoriasisCTRI/2024/06/068896National Research Institute of Unani Medicine for Skin Disorders60
已完成
2 期
Panchathiktha Ghritham as Internal and Kodiveli Thailam as External in the management of Kalanjaga Padai in childrenCTRI/2024/05/067799National Institute of Siddha30
已完成
3 期
A Study to Test the Safety and Effects of Ethniq Skin Revive in Patients with Different Skin Problems.CTRI/2024/10/075477Ethniq Ayush Exports LLP200
尚未招募
2 期
A Clinical Study to find out safety and efficacy of Unani drugs in Childhood PsoriasisCTRI/2024/10/075001Department of Amraze Jild Wa Zohrawiya50